Biosimilar Interchangeability May Be Losing Luster As Approval Goal
Executive Summary
Pricing now may mean more to payers than whether the product is interchangeable.
You may also be interested in...
VA Changes Infliximab Biosimilars; Merck Formulary Win Could Drive Questions On Patient Switching
Move from one infliximab biosimilar to another could illuminate safety concerns surrounding non-medical switching – or at least Janssen hopes so; VA's national formulary moved from Remicade to Pfizer's Inflectra in 2017.
VA Changes Infliximab Biosimilars; Merck Formulary Win Could Drive Questions On Patient Switching
Move from one infliximab biosimilar to another could illuminate safety concerns surrounding non-medical switching – or at least Janssen hopes so; VA's national formulary moved from Remicade to Pfizer's Inflectra in 2017.
Interchangeable Biosimilars: FDA Clarifies US Reference Not Mandatory For Studies
Draft guidance strongly recommends against it, but US FDA's Leah Christl says agency is willing to talk about using foreign-licensed comparators.